ANOLLI, MARIA PAOLA
ANOLLI, MARIA PAOLA
Universita' degli Studi di MILANO
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review
2023 E. Degasperi, M.P. Anolli, P. Lampertico
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics
2023 M.P. Anolli, E. Degasperi, L. Allweiss, A. Sangiovanni, M. Maggioni, C. Scholtes, V. Oberhardt, C. Neumann-Haefelin, M. Dandri, F. Zoulim, P. Lampertico
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination.
2022 R. D'Ambrosio, G. Rizzardini, M. Puoti, S. Fagiuoli, M. Anolli, C. Gabiati, F. D'Amico, L. Pasulo, U. Restelli, M. Colombo, P. Lampertico
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
2022 R. D'Ambrosio, E. Degasperi, M. Anolli, I. Fanetti, M. Borghi, R. Soffredini, M. Iavarone, G. Tosetti, R. Perbellini, A. Sangiovanni, V. Sypsa, P. Lampertico
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
2022 E. Degasperi, M.P. Anolli, P. Lampertico
Bulevirtide for patients with compensated chronic hepatitis delta: A review
2022 E. Degasperi, M.P. Anolli, P. Lampertico